Biotech Startups

BOLD Longevity Growth (BLG) is a venture capital fund focused on investing in companies at the intersection of AI, longevity, and biotechnology. The fund aims to make longevity innovations accessible and affordable for broader populations.

1 investor

BliNK Biomedical develops treatments and therapeutics in the biopharmaceutical industry. The company is led by executives with extensive backgrounds in drug discovery, pharmaceutical development, and biotech commercialization.

1 investor

Bliss BioPharma is a biopharmaceutical company focused on the CMC development and commercialization of biologics, including therapeutic monoclonal antibodies, bispecific antibodies, ADCs, recombinant proteins, and vaccines.

1 investor

Block Biosciences develops first-in-class therapeutics designed to intercept the spread of cancer to the brain by inhibiting a step in the purine biosynthesis pathway involved in brain metastasis. The company designs blood-brain-barrier-permeable inhibitors using a library of clinically-relevant brain metastasis models.

1 investor

Everbloom develops next-generation noble fibers derived from protein waste as biodegradable, recyclable alternatives to synthetic and animal-based textiles like cashmere, wool, and silk. It targets luxury fashion supply chains, partnering with textile mills to provide sustainable materials with lower land, water, and greenhouse gas footprints.

1 investor

Small molecule drug discovery company focused on oncology and autoimmune disorders.

1 investor

Blossom provides contract manufacturing and supply chain services for the pharmaceutical and medical cannabis industries in Europe, specializing in narcotics handling, API manufacturing, and logistics for medical cannabis products.

1 investor

Blue Cell Therapeutics develops an off-the-shelf allogeneic stem cell therapy platform (Blue Cells) that promotes angiogenesis and nerve repair, with a lead candidate (BlueC-231) aimed at treating severe erectile dysfunction in men after radical prostatectomy. The company operates in the biotech and cell therapy space, targeting patients unresponsive to existing drug treatments.

1 investor

Blue Horizon is an investment firm backing founders at the intersection of biology, technology, and agriculture, focusing on creating world-leading platforms through growth and consolidation strategies.

1 investor

BlueBank is a biotech company specializing in microbial, molecular, and biochemical engineering technologies for applications in bio-based products, environmental solutions, and aquaculture.

1 investor

Blueberries Med manufactures standardized bioactive ingredients for the pharmaceutical, cosmetics, and nutraceutical industries, converting biological material into consistent batches suited to regulatory audits and supplier homologation. It provides cGMP production, analytical documentation, and regulatory support to help industrial clients scale formulations and pass recurring audits, with a regulatory presence across Latin America and other markets.

1 investor

BlueCell Bio develops fermentation technologies that break down microalgae cell walls to make Omega-3s and other nutrients more bioavailable, producing sustainable vegan ingredients for human food, animal feed, and pet nutrition. The company is based in Copenhagen, Denmark.

1 investor

BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.

1 investor

Blueprint Biomed develops a patented, off-the-shelf biomaterial implant for bone tissue regeneration that induces natural bone healing without tissue harvesting, added cells, or growth factors. It targets orthopedic and surgical bone-healing procedures, aiming to reduce failed surgeries, complications, and material costs.

1 investor

Blue Rock Therapeutics discovers and develops cell therapies to treat disease and improve patient outcomes. The company operates at the frontier of cell therapy science with a focus on innovation and patient impact.

1 investor

BlueStone Venture Partners is a venture capital firm that invests in portfolio companies across multiple sectors, leveraging operational, technical, and financial expertise from its leadership team.

1 investor

BlueWillow Biologics develops an intranasal vaccine delivery platform using novel oil-in-water emulsion technology to address pandemic preparedness, infectious diseases, and food allergies. The company is a clinical-stage biotech firm with proprietary technology originally discovered at the University of Michigan.

1 investor

b.next develops technologies and infrastructure for building synthetic cells from scratch, working with researchers, universities, governments, and funders. It operates Nucleus, an open technology platform providing materials, protocols, documentation, and software for engineering synthetic cells.

1 investor

BnH Research develops therapeutics for chronic conditions with an initial focus on central nervous system disorders such as Alzheimer's Disease, PTSD, addiction, amblyopia, and stroke, with drug candidates aimed at reopening cortical plasticity. It also provides contract-based research services offering drug efficacy validation data to pharmaceutical companies in early-stage drug discovery, based in South Korea.

1 investor

Boca Bio provides biospecimen sourcing for life sciences research through its BioSpecimen360 offering. It serves researchers who need access to biological specimens.

1 investor

Boltz PBC develops frontier AI models and high-performance compute infrastructure for biomolecular modeling and design, including small-molecule screening and hit discovery. Its tools, available via an API, serve drug discovery and scientific research teams.

1 investor

Bond Biosciences is a clinical-stage biopharmaceutical company developing non-absorbed oral therapeutics that bind excess ions in the gastrointestinal tract to treat ion-related diseases. Its lead candidate, BBI-001, is designed to inhibit dietary iron absorption for patients with iron overload from Hereditary Hemochromatosis.

1 investor

Bonray Bio develops miniaturized microscopy optics and AI-powered image analysis software for reproductive medicine diagnostics, providing male infertility diagnostic instruments and consumables to fertility clinics globally.

1 investor

Bonus Biogroup is a clinical-stage biotechnology company developing tissue engineering and cell therapy products for unmet medical needs related to tissue damage, inflammation, and immune response. Its investigational products include MesenCure, an allogeneic cell therapy targeting inflammation, and BonoFill, a tissue-engineered bone graft for orthopedic and maxillofacial bone defects.

1 investor